Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

We have a unique research and development approach utilizing synthetic lethality and immuno-oncology to target specific proteins and biomarkers in ovarian cancer and endometrial cancer.

We are committed to supporting continued innovation in gynecologic cancers, keeping the patient’s voice at the heart of our mission, and building a pipeline of novel programs to meet their needs